Centogene Extends Strategic Partnership with Takeda to Genetic Testing for Patients with LSDs

Rare Daily Staff

Centogene said it has extended its partnership with Takeda to diagnose patients with lysosomal storage disorders.

Under the renewed one-year partnership agreement, Centogene will continue to provide Takeda with access to diagnostic testing for patients around the world. The aim of the commercial fee-for-service agreement is to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.

“Leveraging our targeted diagnostic portfolio, network of over 30,000 active physicians, and the Centogene Biodatabank driving novel insights, we are uniquely positioned to deliver substantial value to our pharma partners throughout every stage of the development pipeline,” said Ian Rentsch, Centogene chief commercial officer and general manager of pharma. “This collaboration continues to play a vital role in the expansion of Takeda’s world-class enzyme replacement treatments and most importantly, brings life-changing answers to underserved patient communities.”

A key asset to the partnership is the Centogene Biodatabank, which currently contains approximately 700,000 patients representing over 120 highly diverse countries, more than 70 percent of whom are of non-European descent, including a large share of pediatric cases. By integrating multi-omic and multi-ethnic data, the Centogene Biodatabank captures a holistic view to enable the most accurate diagnosis and guide clinical actions.

In January 2015, Centogene originally entered into an agreement with Shire Pharmaceuticals, which was acquired in 2019 by Takeda, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from rare genetic diseases. Last year, the contract was extended until March 2023.

Photo: Ian Rentsch, Centogene chief commercial officer and general manager of pharma